Ling Yin

Message from the Guest Editor

Understanding biological systems requires a seamless integration of molecular insights and systems-level interpretation. In recent years, advances in molecular biology, multi-omics technologies, cellular signaling research, and computational modeling have significantly deepened our understanding of complex biological mechanisms and their translational relevance.

This Special Issue, “Cells to Systems: Molecular Mechanisms with Translational Value,” aims to bring together innovative research that bridges fundamental cellular and molecular discoveries with applied and translational outcomes. By integrating experimental biology with systems-based approaches, we can better elucidate regulatory pathways, stress responses, cellular communication networks, and mechanisms underlying disease and adaptation.

We particularly welcome contributions that demonstrate mechanistic clarity, methodological innovation, and translational potential. Interdisciplinary studies that connect laboratory findings with agricultural, biomedical, environmental, or therapeutic applications are strongly encouraged.

Through this Special Issue, we hope to foster meaningful scientific dialogue and encourage collaborative research that advances both theoretical understanding and real-world impact.

I look forward to receiving your valuable contributions.

Ling Yin
Department of Hortscience
South China Agricultural University, China
Guest Editor

Dr. Ling Yin is currently an Academic Editor at Anhui Medical University and an Associate Professor at the Hefei Comprehensive National Science Center in China. She earned her PhD from South China Agricultural University in 2016 and has since conducted postdoctoral research at Fudan University and the University of Florida College of Medicine. Her research lies at the intersection of cancer immunology, gene therapy, and precision medicine, with a particular focus on multi-omics integration, AAV-based gene delivery systems, and immunomodulatory mechanisms in tumors and inflammatory diseases.

Dr. Yin has authored over 30 peer-reviewed publications in high-impact journals such as Drug Discovery Today, Frontiers in Immunology, Molecular Therapy, and Journal of Medical Virology. She serves as a reviewer for prestigious journals including Gut, Cell Reports Medicine, and Clinical and Translational Medicine, and holds editorial roles with Frontiers in Immunology, Global Translational Medicine, iNew Medicine, and IntechOpen. She has also served as a conference speaker, session chair, and committee member at numerous international scientific gatherings.

Her contributions to biomedical research have been recognized with several awards, including the Global Recognition Award (2024, 2026) and the High-Caliber Talent of Hefei City (2025). Dr. Yin is committed to advancing translational research that bridges molecular mechanisms and clinical applications.

Web of Science Researcher ID: LIC-3245-2024

ORCID | LinkedIn | GoogleScholar | Web of Science / Publons | Loop | Academia.edu | SSRN

1. Adra2a Knockdown Attenuates EMT-Associated Airway Remodeling in Allergic Asthma via cGMP/PKG Signaling (2026)
2. From Cancer Treatment Strategy to Cancer Survivorship Care: Advances in Multi-Omics and AI Integration (2025/2026)
3. Bivalent Aptamer Assemblies: A Versatile Toolkit for Precision Targeting of B-Cell Malignancies (2026)
4. Schisantherin A: Remodeling Gut Microbiota to Activate the Gut–Immune–Neural–Adipose Axis for Thermogenesis (2026)
5. High-throughput sequencing unveils tumor immune interactions: From genomic alterations to clinical translation (2025)
6. Sulforaphane in cancer precision medicine: from biosynthetic origins to multiscale mechanisms and clinical translation (2025)
7. Synergistic Frontiers in Oncology: Integrating Antibody-Drug Conjugates and Immune Checkpoint Inhibitors for Tumor Microenvironment Reprogramming (2025)
8. Adeno-associated virus as a powerful tool for gene therapy (2025)
9. ErbB/HER Family in Cancer Immunology: Therapeutic Advances and Mechanisms (2025)
10. Cancer Stem Cells in Personalized Therapy: Mechanisms, Microenvironment Crosstalk, and Therapeutic Vulnerabilities (2025)
11. Revolution of AAV in Drug Discovery: From Delivery System to Clinical Application (2025)
12. NLRP3 Inflammasome: From Drug Target to Drug Discovery (2025)
13. Combination Therapy of Bevacizumab and Galunisertib Extend TVN Time Window (2024)
14. Using gene therapy to circumvent limitations of TRAIL-based cancer therapy (2024)
15. Disease mechanisms of X-linked cone dystrophy caused by missense mutations in the red and green cone opsins (2021)
16. AAV3-miRNA vectors for growth suppression of human hepatocellular carcinoma cells in vitro and human liver tumors in a murine xenograft model in vivo (2021)
17. Enhanced transduction of human hematopoietic stem cells by AAV6 vectors: Implications in gene therapy and genome editing (2020)